Abatacept:The first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 8, Issue 1, 2008, Pages 115-122

  Chitale, Sarang ^a   Moots, Robert ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Abatacept; Biologies; CTLA 4; CTLA4 Ig; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; BELATACEPT; CD4 ANTIGEN; CD86 ANTIGEN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HELPER CELL; HUMAN; INFECTION; INFLAMMATORY CELL; INHIBITION KINETICS; LICENCE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; REVIEW; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; T-LYMPHOCYTES;

EID: 38949185084     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.1.115     Document Type: Article

References (38)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81
2. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care based inception cohort. Arthritis Rheum 2005;52:2293-9
3. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46(8):2010-19
4. Grigor C, Capell H, Stirling A, et al. Effect of treatment strategy of tight control for rheumatoid arthritis (TICORA): a single blind, randomised control trial. Lancet 2004;364:263-9
5. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
6. Moreland I, Bate G, Kirkpatrick P Abatacept. Nat Rev Drug Discov 2006;5:185-6
7. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11(5):S55-S62
8. Stuart RW, Racke MK. Targeting T-cell co-stimulation in auto-immune diseas Expert Opin Ther Targets 2002;6:275-89
9. Fox DA. The role of T-cells in the immunopathogenesis of RA. new perspectives. Arhtritis Rheum 1997;40:598-609
10. Van Boxel JA, Paget SA. Predominantly T-cell inflitrate in rheumatoid synovial membranes. N Engl J Med 1975;293(11):517-20
11. Klimiuk. PA, et al. Production of cytokines and metalloproteinases in rheumatoid arthritis is T-lymphocyte dependant. Clin Immunol 1999;90:65-78
12. Liu MF, Kohsaka H, Sakurai H, et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 1996;39(1):110-14
13. MacDonald KP, Nishioka Y, Lipsky PE, Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997;100(9):2404-14
14. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisimd. Annu Rev Immunol 2005;23:515-48
15. Sharpe AH, Abbas KA. T-cell costimulation. Biology, Theraputic potential and Challenges. N Engl J Med 2006;355(10):973-5
16. Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B-lymphocyte depletion with rituximab in rheumatoid arthritis in 7 years. Rheumatology 2007;46(4):626-31
17. Van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the Tempo Trial. Ann Rheum Dis 2006;65(3):328
18. Maddison P, Kedy P. Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 2005;44(3):280-6
19. Reiser H, Stadeker MJ. Co-stimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369-77
20. Linsley PS, Brady W, Urnes M, Grosmaire IS, Damle MK, Ledbetter JA. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991;174:561-9
21. Linsley PS, et al. Immunosuppresion in vivo by a soluble form of CTLA4 T-cell activation molecule. Science 1992;257:729-95
22. FDA labelling information. Available at: URL:www.fda.gov/Gder/foi/label/ 2005/1251181bl.pdf> (2005)
23. Boyce EG. Abatacept: the first co-stimulation modulator for use in RA. Formulary 2006;41(7):322-6
24. Moreland LW, Alten R, Van den Bosch F, et al. Co-stimulatory blockade in patients with rheumatoid arthritis: a pilot, dose finding, double blind, placebo controlled clinical trialevaluating CTLA-4 Ig and LEA 29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9
25. Kremer JM, Westhovens R, Leon M, et al. treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA-4 Ig. N Engl J Med 2003;349:1907-15
26. Kremer JM, Dougados M, Emery R et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-71
27. Weinblart M, Schiff M, Goldman A. Kremer J. Selective co stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66(2):228
28. Kremer JM, Genent HY, Moreland LW, et al. Effects of abaracept in patients with methotrexate-resistant active rheumatoid arthritis: a Randomized Trial. Ann Intern Med 2006:144(12):865-76
29. Enovese MC, et al. Abatacept for rheumatoid arthritis refractory to TNF-alpha inhibition. New Engl Med J 2005;353:1114-23
30. Weinblart M, Combe B, Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54(9):2807-16
31. Golimumab (CNTO 148) shows clinical benefit in active rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting; 2005
32. Chugai Pharmaceutical company Ltd. Tocilizumab monotherapy reported to slow joint damage in patients with RA. Data presented at ACR, San Diego; 2006
33. EMEA/144134/2007; London March 2007
34. EMEA/CHMP/72407/2007; London, March 2007
35. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with Abatacept, who have inadequaw response to anti-TNF therapy in a double blind, placebo controlled, multicentre randomised clinical trial. Rheumatology 2006;45:1238-46
36. Emery P, Kosinsky M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumol 2006;33(4):681-9
37. Weisman M, Durez P, Hallegua D, Nuamah I, Vratsanos G, Beckcr JC. Abatacept inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. Ann Rheum Dis 2004;63(Suppl 1):i138 (Abstract)
38. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16